Stay updated on REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial

Sign up to get notified when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision label updated from v3.3.3 to v3.3.4.
    Difference
    0.0%
    Check dated 2026-01-14T01:52:15.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    21 days ago
    No Change Detected
  4. Check
    28 days ago
    Change Detected
    Summary
    Added Revision: v3.3.3 at the bottom of the page; removed HHS Vulnerability Disclosure and Revision: v3.3.2.
    Difference
    0.1%
    Check dated 2025-12-23T12:29:52.000Z thumbnail image
  5. Check
    50 days ago
    Change Detected
    Summary
    Revision label updated from v3.3.1 to v3.3.2 in the page footer. This is a minor maintenance update and does not affect study information.
    Difference
    0.0%
    Check dated 2025-12-01T17:26:53.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    A new revision label 'Revision: v3.3.1' was added and the previous 'Revision: v3.2.0' label was removed.
    Difference
    0.0%
    Check dated 2025-11-24T14:36:24.000Z thumbnail image
  7. Check
    64 days ago
    Change Detected
    Summary
    A government funding/operating status notice was removed from the page; the study details and contact information remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-11-17T06:54:21.000Z thumbnail image
  8. Check
    78 days ago
    Change Detected
    Summary
    There are no significant additions or deletions to core page content; the page appears to retain the same sections such as Study Overview, Eligibility Criteria, Study Plan, and Contacts/Locations, with only minor visual adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-11-03T01:17:56.000Z thumbnail image

Stay in the know with updates to REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.